Nonheritable cellular variability accelerates the evolutionary processes of cancer

PLoS Biology

Volumn 10, Issue 4, 2012, Pages

  Frank, Steven A ^a,b   Rosner, Marsha Rich ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTATION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL HETEROGENEITY; CELL SURVIVAL; DRUG RESISTANCE; DRUG SENSITIVITY; EVOLUTION; GENE MUTATION; GENETIC VARIABILITY; HERITABILITY; HOMEOSTASIS; HUMAN; METASTASIS; PHENOTYPIC VARIATION; CELL TRANSFORMATION; NEOPLASM; PATHOLOGY; PHENOTYPE;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; HOMEOSTASIS; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 84859974816     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001296     Document Type: Article

References (44)

1. Hanahan D, Weinberg R. A, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Nowell P. C, (1976) The clonal evolution of tumor cell populations. Science 194: 23-28.
3. Greaves M, Maley C. C, (2012) Clonal evolution in cancer. Nature 481: 306-313.
4. Komarova N. L, Wodarz D, (2005) Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 102: 9714-9719.
5. West-Eberhard M. J, (2003) Developmental plasticity and evolution Oxford; New York Oxford University Press.
6. Suel G. M, Kulkarni R. P, Dworkin J, Garcia-Ojalvo J, Elowitz M. B, (2007) Tunability and noise dependence in differentiation dynamics. Science 315: 1716-1719.
7. Losick R, Desplan C, (2008) Stochasticity and cell fate. Science 320: 65-68.
8. Yang R, Niepel M, Mitchison T. K, Sorger P. K, (2010) Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin Pharmacol Ther 88: 34-38.
9. Altschuler S. J, Wu L. F, (2010) Cellular heterogeneity: do differences make a difference? Cell 141: 559-563.
10. Niepel M, Spencer S. L, Sorger P. K, (2009) Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr Opin Chem Biol 13: 556-561.
11. Kaneko K, (2011) Characterization of stem cells and cancer cells on the basis of gene expression profile stability, plasticity, and robustness: dynamical systems theory of gene expressions under cell-cell interaction explains mutational robustness of differentiated cells and suggests how cancer cells emerge. Bioessays 33: 403-413.
12. Sigal A, Milo R, Cohen A, Geva-Zatorsky N, Klein Y, et al. (2006) Variability and memory of protein levels in human cells. Nature 444: 643-646.
13. Chang H. H, Hemberg M, Barahona M, Ingber D. E, Huang S, (2008) Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 453: 544-547.
14. Spencer S. L, Gaudet S, Albeck J. G, Burke J. M, Sorger P. K, (2009) Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459: 428-432.
15. Gupta P. B, Fillmore C. M, Jiang G, Shapira S. D, Tao K, et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146: 633-644.
16. Roesch A, Fukunaga-Kalabis M, Schmidt E. C, Zabierowski S. E, Brafford P. A, et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
17. Bissell M. J, Hall H. G, Parry G, (1982) How does the extracellular matrix direct gene expression? J Theor Biol 99: 31-68.
18. Huang S, Eichler G, Bar-Yam Y, Ingber D. E, (2005) Cell fates as high-dimensional attractor states of a complex gene regulatory network. Phys Rev Lett 94: 128701.
19. Huang S, Ernberg I, Kauffman S, (2009) Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol 20: 869-876.
20. Rubin H, (1990) The significance of biological heterogeneity. Cancer Metastasis Rev 9: 1-20.
21. Chmielecki J, Foo J, Oxnard G. R, Hutchinson K, Ohashi K, et al. (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3: 90ra59.
22. Larder B. A, Kemp S. D, Harrigan P. R, (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
23. Bonhoeffer S, May R. M, Shaw G. M, Nowak M. A, (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci U S A 94: 6971-6976.
24. Baldwin J. M, (1896) A new factor in evolution. American Naturalist 30: 441-451.
25. Waddington C. H, (1942) Canalization of development and the inheritance of acquired characters. Nature 154: 563-565.
26. Waddington C. H, (1953) Genetic assimilation of an acquired character. Evolution 7: 118-126.
27. Schlichting C. D, Pigliucci M, (1998) Phenotypic evolution: a reaction norm perspective Sunderland, Massachusetts Sinauer Associates.
28. Ancel L. W, (2000) Undermining the Baldwin expediting effect: Does phenotypic plasticity accelerate evolution? Theor Popul Biol 58: 307-319.
29. Price T. D, Qvarnstrom A, Irwin D. E, (2003) The role of phenotypic plasticity in driving genetic evolution. Proc Biol Sci 270: 1433-1440.
30. Pigliucci M, Murren C. J, Schlichting C. D, (2006) Phenotypic plasticity and evolution by genetic assimilation. J Exp Biol 209: 2362-2367.
31. Lande R, (2009) Adaptation to an extraordinary environment by evolution of phenotypic plasticity and genetic assimilation. J Evol Biol 22: 1435-1446.
32. Frank S. A, (2011) Natural selection. II. Developmental variability and evolutionary rate. J Evol Biol 24: 2310-2320.
33. Fierst J. L, (2011) A history of phenotypic plasticity accelerates adaptation to a new environment. J Evol Biol 24: 1992-2001.
34. Holland J. H, (1975) Adaptation in natural and artificial systems Ann Arbor University of Michigan Press.
35. Singh D. K, Ku C. J, Wichaidit C, Steininger R. J 3rd, Wu L. F, et al. (2010) Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities. Mol Syst Biol 6: 369.
36. Sharma S. V, Lee D. Y, Li B, Quinlan M. P, Takahashi F, et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
37. Kussell E, Kishony R, Balaban N. Q, Leibler S, (2005) Bacterial persistence: a model of survival in changing environments. Genetics 169: 1807-1814.
38. Wiuff C, Zappala R. M, Regoes R. R, Garner K. N, Baquero F, et al. (2005) Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother 49: 1483-1494.
39. Lewis K, (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5: 48-56.
40. Frei E 3rd, Karon M, Levin R. H, Freireich E. J, Taylor R. J, et al. (1965) The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26: 642-656.
41. Zdanowicz M. M, (2006) The pharmacology of HIV drug resistance. Am J Pharm Educ 70: 100.
42. Levy S. F, Siegal M. L, (2008) Network hubs buffer environmental variation in Saccharomyces cerevisiae. PLoS Biol 6: e264 doi:10.1371/journal.pbio.0060264.
43. Murphy K. M, Travers P, Walport M, (2007) Janeway's immunobiology Boca Raton, Florida Garland Science.
44. Frank S. A, (2002) Immunology and evolution of infectious disease Princeton, New Jersey Princeton University Press.